Related references
Note: Only part of the references are listed.Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
Pauline De Bruyn et al.
CURRENT OPINION IN ONCOLOGY (2019)
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Posttransplant Malignancy
Ana P. Rossi et al.
SURGICAL CLINICS OF NORTH AMERICA (2019)
Skin Cancer Following Solid Organ Transplantation: A Review of Risk Factors and Models of Care
Matthew D. Howard et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results
Jacques Dantal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Etiology of increased cancer incidence after solid organ transplantation
Sergio A. Acuna
TRANSPLANTATION REVIEWS (2018)
Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
Ouidad Zehou et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report
Jonathan W. Goldman et al.
BMC NEPHROLOGY (2018)
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Martin Tio et al.
EUROPEAN JOURNAL OF CANCER (2018)
Immune checkpoint inhibitors in the management of malignancies in transplant recipients
Dileep Kumar Reddy Regalla et al.
POSTGRADUATE MEDICAL JOURNAL (2018)
Urologic malignancies in kidney transplantation
Laura A. Hickman et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy
Leslie S. Kean et al.
IMMUNOLOGICAL REVIEWS (2017)
Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature
Julia K. Winkler et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab
Richard Barnett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient
Clement Deltombe et al.
TRANSPLANTATION (2017)
Clinical and Pathological Analyses of Cases of Acute Vascular Rejection After Kidney Transplantation
T. Shimizu et al.
TRANSPLANTATION PROCEEDINGS (2017)
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
Julia Escandon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration
C-K Wu et al.
ANNALS OF ONCOLOGY (2017)
Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients
J. C. Krisl et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
De novo cancer after solid organ transplantation: Epidemiology, prognosis and management
Aude Guillemin et al.
BULLETIN DU CANCER (2017)
Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy
C. L. Boils et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection
T. Alhamad et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
L. Spain et al.
ANNALS OF ONCOLOGY (2016)
The Basis of Oncoimmunology
A. Karolina Palucka et al.
CELL (2016)
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
Saskia Herz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Tumor Regression and Allograft Rejection after Administration of Anti-PD-1
Evan J. Lipson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mixed acute kidney allograft rejection after an antiprogrammed cell death protein 1 antibody treatment for lung epidermoid carcinoma
Mathilde Tamain et al.
TRANSPLANT INTERNATIONAL (2016)
Oral Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor Inhibitor Sunitinib Prevents Chronic Allograft Injury in Experimental Kidney Transplantation Model
Jukka M. Rintala et al.
TRANSPLANTATION (2016)
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Michael Ong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
Naoka Murakami et al.
CLINICAL KIDNEY JOURNAL (2016)
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L. Apetoh et al.
ANNALS OF ONCOLOGY (2015)
Chronic allograft rejection: a fresh look
Johannes Wedel et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2015)
Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival
Romina Fasciani et al.
INTERNATIONAL OPHTHALMOLOGY (2015)
Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Malignancy-related mortality following kidney transplantation is common
Daniela Farrugia et al.
KIDNEY INTERNATIONAL (2014)
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Sylvie Euvrard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation
Markus Guba et al.
TRANSPLANT INTERNATIONAL (2012)
Recent advances in immunosuppressive therapy for prevention of renal allograft rejection
Keri E. Lunsford et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2011)
Corneal Graft Surgery Combined with Subconjunctival Bevacizumab (Avastin)
Richard J. Symes et al.
CORNEA (2010)
Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses
Astrid Starke et al.
KIDNEY INTERNATIONAL (2010)
Acute renal allograft rejection is associated with increased levels of vascular endothelial growth factor in the urine
Wenhan Peng et al.
NEPHROLOGY (2008)
PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection
Katsunori Tanaka et al.
JOURNAL OF IMMUNOLOGY (2007)
Impairment of CD4+CD25+ regulatory T-cells in autoimmune liver disease
MS Longhi et al.
JOURNAL OF HEPATOLOGY (2004)
Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: Enhanced cell cycle progression promotes recall antigen responsiveness
TL Vanasek et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
